- Home
- SRCE vs RCUS Comparison
SRCE vs RCUS Comparison
Compare SRCE & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRCE
- RCUS
- Stock Information
- Founded
- SRCE 1863
- RCUS 2015
- Country
- SRCE United States
- RCUS United States
- Employees
- SRCE N/A
- RCUS N/A
- Industry
- SRCE Major Banks
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- SRCE Finance
- RCUS Health Care
- Exchange
- SRCE Nasdaq
- RCUS Nasdaq
- Market Cap
- SRCE 1.4B
- RCUS 1.4B
- IPO Year
- SRCE N/A
- RCUS 2018
- Fundamental
- Price
- SRCE $57.85
- RCUS $14.02
- Analyst Decision
- SRCE Hold
- RCUS Buy
- Analyst Count
- SRCE 2
- RCUS 12
- Target Price
- SRCE $64.75
- RCUS $34.50
- AVG Volume (30 Days)
- SRCE 62.4K
- RCUS 609.3K
- Earning Date
- SRCE 01-23-2025
- RCUS 02-19-2025
- Dividend Yield
- SRCE 2.49%
- RCUS N/A
- EPS Growth
- SRCE 2.45
- RCUS N/A
- EPS
- SRCE 5.25
- RCUS N/A
- Revenue
- SRCE $369,012,000.00
- RCUS $263,000,000.00
- Revenue This Year
- SRCE N/A
- RCUS $127.65
- Revenue Next Year
- SRCE $1.11
- RCUS N/A
- P/E Ratio
- SRCE $11.03
- RCUS N/A
- Revenue Growth
- SRCE 1.57
- RCUS 119.17
- 52 Week Low
- SRCE $47.30
- RCUS $13.51
- 52 Week High
- SRCE $68.13
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- SRCE 43.01
- RCUS 37.13
- Support Level
- SRCE $56.77
- RCUS $13.81
- Resistance Level
- SRCE $59.08
- RCUS $14.52
- Average True Range (ATR)
- SRCE 1.46
- RCUS 0.60
- MACD
- SRCE 0.18
- RCUS -0.09
- Stochastic Oscillator
- SRCE 69.79
- RCUS 22.97
About SRCE 1st Source Corporation
1st Source Corp along with its subsidiary offers banking services. The bank provides Commercial, Agricultural, and Real Estate Loans which are given to privately owned business clients mainly located within regional market area, Consumer Services that consists of full range of consumer banking products and services, Trust and Wealth Advisory Services and Insurance services to individuals and business clients. Its Specialty Finance Group offers financing services for construction equipment, new and pre-owned private and cargo aircraft, and various vehicle types for fleet purposes.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.